Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 1.6 hours |
Excretion | renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
ECHA InfoCard | 100.124.957 |
Chemical and physical data | |
Formula | C12H15N |
Molar mass | 173.259 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered at American Cyanamid as an analgesic drug candidate, and licensed to DOV Pharmaceutical in 1998 after American Cyanamid was acquired by Wyeth. [1] [2] [3]
In January 2007, Dov licensed the rights to bicifadine to XTL Biopharmaceuticals after bicifadine failed in a Phase III clinical trial for chronic lower back pain. [4] [5] [6] XTL ran a PhaseIIb clinical trial for pain caused by diabetic neuropathy, which failed in 2008; [7] XTL terminated the agreement in 2010. [8] In 2010 Dov was acquired by Euthymics Bioscience which intended to continue development of other candidates from Dov's portfolio. [9]
Bicifadine has a non- opioid, non- NSAID mechanism for the treatment of pain, which should have less abuse potential than opioid drugs and less propensity to cause gastric ulcers than NSAID drugs. [10] While the drug is purported to be a serotonin (SERT) and noradrenaline transporter (NET) inhibitor, it also has effects at the dopamine transporter (DAT), effectively making it a broad-spectrum monoamine transporter inhibitor or " triple reuptake inhibitor." [11]
Clinical data | |
---|---|
Routes of administration | Oral |
ATC code |
|
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Elimination half-life | 1.6 hours |
Excretion | renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
ECHA InfoCard | 100.124.957 |
Chemical and physical data | |
Formula | C12H15N |
Molar mass | 173.259 g·mol−1 |
3D model ( JSmol) | |
| |
| |
(what is this?) (verify) |
Bicifadine (DOV-220,075) is a serotonin-norepinephrine-dopamine reuptake inhibitor (SNDRI) discovered at American Cyanamid as an analgesic drug candidate, and licensed to DOV Pharmaceutical in 1998 after American Cyanamid was acquired by Wyeth. [1] [2] [3]
In January 2007, Dov licensed the rights to bicifadine to XTL Biopharmaceuticals after bicifadine failed in a Phase III clinical trial for chronic lower back pain. [4] [5] [6] XTL ran a PhaseIIb clinical trial for pain caused by diabetic neuropathy, which failed in 2008; [7] XTL terminated the agreement in 2010. [8] In 2010 Dov was acquired by Euthymics Bioscience which intended to continue development of other candidates from Dov's portfolio. [9]
Bicifadine has a non- opioid, non- NSAID mechanism for the treatment of pain, which should have less abuse potential than opioid drugs and less propensity to cause gastric ulcers than NSAID drugs. [10] While the drug is purported to be a serotonin (SERT) and noradrenaline transporter (NET) inhibitor, it also has effects at the dopamine transporter (DAT), effectively making it a broad-spectrum monoamine transporter inhibitor or " triple reuptake inhibitor." [11]